Celgene reports positive results in late-stage trial of treatment for breast cancer

KeepHealthCare.ORG – Celgene reports positive results in late-stage trial of treatment for breast cancer

Celgene Corp.












CELG, +0.52%










reported positive results from a late-stage trial of a treatment for breast cancer Tuesday, saying the trial met its co-primary endpoint of progression-free survival. The trial, which was sponsored by Roche, involved 902 patients and sought to evaluate the combination of the investigational combination TECENTRIQ plus ABRAXANE in triple negative breast cancer, a type that has a high unmet need. “This is the first phase III study to demonstrate a statistically significant PFS improvement in first-line metastatic or unresectable locally advanced triple negative breast cancer (TNBC),” Celgene said in a statement. The results will be presented at a coming medical meeting. Celgene shares rose 2% premarket on the news but have fallen 19.7% in 2018 through Monday, while the S&P 500












SPX, +0.30%










has gained 4.1%.

Source: https://www.marketwatch.com/story/celgene-reports-positive-results-in-late-stage-trial-of-treatment-for-breast-cancer-2018-07-10

Leave a Reply

Your email address will not be published. Required fields are marked *